Actively Recruiting
Lemborexant Treatment of Insomnia Linked to Epilepsy
Led by University of Manitoba · Updated on 2025-02-13
26
Participants Needed
2
Research Sites
128 weeks
Total Duration
On this page
Sponsors
U
University of Manitoba
Lead Sponsor
D
Duke University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to assess whether Lemborexant can improve sleep in patients with epilepsy.
CONDITIONS
Official Title
Lemborexant Treatment of Insomnia Linked to Epilepsy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Sleep-related focal epilepsy
- Use of contraception
You will not qualify if you...
- Changes in antiseizure medication 1 month before or during the study
- Use of concomitant medications per SUNRISE1
- Hepatic impairment
- Female participants who are pregnant or breastfeeding
- Compromised respiratory function
- History of complex sleep-related behaviour
- Rare hereditary diseases such as galactosemia or glucose-galactose malabsorption
- History of dependence, tolerance, abuse, or rebound insomnia
- Psychiatric disorders with abnormal thinking, behavioural changes, depression, or suicidal ideation
- Diagnosis of narcolepsy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Duke University
Durham, North Carolina, United States, 27708
Not Yet Recruiting
2
Health Sciences Centre
Winnipeg, Manitoba, Canada, R3A1R9
Actively Recruiting
Research Team
M
Marcus C Ng, MD, FRCPC
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here